eli lilly is building two new manufactures plants to try to meet this demand. we got an exclusive look inside to see just how they're trying to meet it. take a look. >> helping us lose weight. >> reporter: some most in-demand medicines in the world. >> wa kovi, fda approved for weight-loss. diabetes drugs ozempic. >> mounjaro, and lose up to 25 pounds railroad the final three moss of last year 9 million prescriptions for drugs like these. a 300% increase since 2020. without insurance a one-month supply of one of these drugs can cost more than $1,000. all three are on the fda's list of drugs in short supply. by end of the year, mounjaro's manufacturer eli lilly expects fda approve toll treat obesity and potentially millions more people seeking it out. >> it's our own responsibility to scale these fast as we can. >> reporter: we got exclusive access to this mounjaro manufacturing plant in durham, north carolina, where the company is ramping up supply. in this room, showing us how it takes only milliseconds to fill the drug into syringes. >> how many can this do i

how could you possibly figure out i was looking at pharmaceuticals and eli lilly? of starbucks? >> that's the question. mike murphy hasn't blinked in four minutes. [laughter] i'm leaving you wanting more. that's how you do it, the magic of compounded interest. eli lilly, or i'm not bullish or bearish, but we're investing that money in a 529. stuart: that was fantastic. stay with us for just a moment. >> sure. stuart: i've just got to continue the show and see what we're doing. it's time for the tuesday trivia question. what is the most popular halloween candy? skittles? m m&ms? sour patch kids or reese's peanut butter cups? oz is going to guess -- no, oz isn't going to guess, oz to knows. [laughter] when we come back. ♪ you can't buy great conversations or moments that matter, but you can invest in them. at t. rowe price our strategic investing approach .. t. rowe price, invest with confidence. this is spring semester at over 13,000 us school districts, which have become top targets for ransomware attacks. but there's never been a reported ransomware attack on a ch

coming up, eli lilly sees a bright future with this agile new drug.? stick with cramer. >>> nonsense about this new class of weight loss drugs. think ozempic, we govy. mounjaro. i own a ton of lilly for the charitable trust because r precise will i because this diabetes slash weight loss drug that can help with blood pressure. also curtailing heavy drinking and people sufferingmounjaro's approved for diabetes but it's selling like mad. hard to find. novo nordisk has approval for both. lilly expects mounjaro to be approved for weight loss by the end of the year although it's already being used off label. i want to make it clear because it's just now dawning on people there could be a real disruption here. i wouldn't be surprised if it alters the way people eat and drink stushlly. just yesterday waufrmt the largest grocer in the country said it's beginning to have an impact on sales. suddenly they recognize there could be a big bottom line impact for everything in the food and beverage base. when walmart makes these comments you go from anecdotal worrie

carleton: andrew, big story of the year end tabloids, weight loss drugs like eli lilly and it seems likehere affecting more of the healthcare that a been upset with the earlier. >> america has been coming a ozempic nation in the beginning to embrace the diet drugs. they are focused on the downside of what companies could be losers from this. walmart said people who buy the drugs are consuming less food or buying less food so that was a broad selloff of food stock, salty snacks and junk food and soda and beer a big selloff on coke, pepsi, monda lees, anheuser-busch and many of the stocks within over 5% with 52 week lows. carleton: you bet against or room for upside. >> pepsico and coked down 5% this week. they're yielding about 3% plus, 20 times earnings in the business is durable. i would not bet against the american either. and you have 1 million or 2 million americans on the drugs right now even if it grows dramatically i don't think you have a big impact on the companies and their sales. carleton: don't bet against the american either, i love it. elizabeth last year 2022 was a story o

i'm focused on the upcoming launch of other drugs and what that looks like for eli lilly stock.ff. too early to say what kind of impact that will have on what we eat and consume. remember, these are serious drugs for patients with serious metabolic disease. guy: long-term, how big do think the potential market is? this feels like the ai craze from early on. everyone is trying to figure out what the ultimate impact will be. will ozempic ultimately impact all of our lives? >> it is not just ozempic, it is other drugs in development. i don't know if it will affect all of our lives, but it will for those who have bmi's above 27, who are obese. we think the obesity market alone, not diabetes, could be greater than $70 billion in the u.s. 100 plus billion dollars globally. this could be one of the largest markets in pharmaceutical history. alix: this raises an interesting question. if we pair it with ai, when nvidia came out with some serious revenue numbers behind it, all ai stocks moved higher. any company that mentioned ai got a boost. this earnings season, do you think it will be

i would be buying eli lilly, i would be buying novo. you were spot on. thank you for that.nce listened to you, they're up big. tell me about novo which makes ozempic. >> these companies have exploded. what's interesting is this is in the obesity market. people are getting ozempic or nujaro not with prescriptions for type 2 diabetes, they're running in and begging their doctors to get them these drugs. novo can't make enough of ozempic. last year cornell's weight loss center saw 20,000 patients just in this little center, so unbelievable. and for example, eli lilly which couple of years ago had a market cap of about 100 billion, its market cap is now 520 billion. maria: wow. >> unbelievable. maria: unbelievable. >> novo has a value that's greater than the gdp of the country it's in, denmark. maria: unbelievable. >> it's the most valuable company in europe, more valuable than lvmh. so the obesity markets has taken over the world and i think we'll see in the future that wh where humira for autoimmune diseaseses had a value making 18 billion a year, we'll see these drugs making

i have nvidia , tesla, mcardle libre, eli lilly and service now. >> interesting.on yesterday. second-best -- equal to microsoft. nvidia we know that is high multiple. don't expect it to round on the quarter. this is for -- this is artificial intelligence and this is going to be automation. tesla we know is getting hammered but it is electric but also electric technology which is what you can still only. mcardle libre is the ebay of latin america. and that eli lilly reports next week and we know that is gop and has a great diabetes franchise and it will have an amazing anti-altheimer franchise , drug, auction, auto, automation and ai. it's different enough. someone who is really tough may say, you're going to let nvidia service now be the same person? i'm willing to say yes because they are trading in different markets. let's take a call from david in north carolina. >> hey, jim. talking to you again. >> thank you for calling. >> my oil had tremendous seasons. maybe next year we will repeat the 1983. >> wouldn't that be fantastic? that's part of the problem that i

we have taken some off the table for our charitable trust we've had a really good run with eli lilly and we felt we were being greedy so i took some off. you should join the club because we've got some really good calls on eli lilly let's go to chris in california. chris. >> caller: hi. >> hey, chris. >> caller: mr. cramer. >> indeed. what's up? >> caller: you are great and i've been watching your tv for many years >> thank you okay >> caller: the question? >> yeah. >> caller: yeah, my question was on macy's. so should i buy more macy's? should i sell -- >> macy "uss a very inexpensive stock, 5.5% yield but later in the show you'll hear i don't think yield's really helping stocks i don't think you're going to get hurt buying a little bit here but it's a retailer and i do not like retailers. i just don't i like to talk to the guys who run retailers. i like retail in a better environment. not fighting the fed when rates keep getting higher. this might not be the crescendo i want yet but you've got to prepare for when the time comes and have your shopping list ready. i've just given you

and cnn got access to an eli lilly plant, and it could get approval for weight loss by the tend of-- the end of the year. >> reporter: they are some of the most in demand drugs for weight loss, wygovy and weight loss. also mounjaro. in the last year over 9 million prescriptions for these drugs, and without insurance, and one-month supply of these drugs can cost more than $1,000, and all three are on the fda drugs in short supply. by the end of the year, mownjaro's drug is expected to be getting fda approval for weight loss, and millions seeking it out. >> i feel like we need to fill this as fast as we can. >> reporter: we received exclusive access to this plant. in this, plant manager says it takes milliseconds to fill this drug into the syringes. how many can you do in an hour? >> this is a high-speed filling machine, and on the annual basis, this is going to fill millions of syringes. >> reporter: they are running the factory 24/7 and tracking every step of the operational long the way. you are able to see every batch as it flows through the facility. >> reporter: is it common for

stuart: if you show me eli lilly it is a new high. i think it is. moments ago.ns, these 2 are soft, because ozempic showed success in the trial, additional uses for the diabetes and weight loss drugs, eli lilly is attached to this because they made more. stuart: that story just rolls on and on. it never stops. president biden reaffirmed us support for israel. peter doocy at the white house, does that support include refreezing funds from iran or sending troops? >> we are told by people in the pentagon the us has some door kickers on standby in the region waiting for orders if they ever come and special operators and intel experts in the us have been deployed to help israeli officials plan whatever it is they are planning next. as for refreezing $6 billion for iran, a country understood to have supported and possibly bankrolled this operation it doesn't sound like that will happen yet. >> is that reason to refreeze the $6 billion they helped unlocked for them to get in exchange for the prisoners? >> we cannot yet had a dollar of that 6 billion spent and i will le

eli lilly's drug helps people lose weight for almost a year during a stud any y in china wi 16% weight loss in weeks late stage trials begin later this year. shares are higher in the pre-market 4.5% for innovent. >> losing 16% of the body weight >> that sounds like a lot. >> i'll get a calculator later silvana, see you later on. >>> we turn attention to the developing story with the war with israel and hamas. over the weekend, israel started the second stage demploying ground operations. deborah haynes, from sky news, joins us give us a sense of what is going on right now >> reporter: good morning. we heard another israeli war plane up ahead all morning, a lot of air strikes into gaza. we they have been hitting across this part of the strip we saw a strike to the northern tip over there you see a few strikes there, but earlier this morning, we counted about eight war planes, some moving in formation of four and they seem to be targeting in that direction which is toward gaza city. you might be able to hear a boom there is artillery positions over in that direction firing on to gaza in

. >> eli lilly and knovo nordisk have been taking the lead in this space, but our next guest says someut. jared holz joins us on-set to make the long case for these particular stocks. and hes caralth care overall han terrible but these two names. and investors that might want to cycle out of these names, take some money off the table, you are looking at three others. >> yeah, i think so, i'm trying to find other means of hope in a sector that's been terrible for most of the year. i mean, it's really very -- there's very narrow leadership, lilly and novo, we've discussed so many times this year. there have to be other things to own. so, i think abbvie, for me, in large cap far ma, is pretty well positioned. they are going through their patent law as we speak. we don't have to wait and fear for 2027, '28, '29. we're in it now. they're introducing new products and markets that they know very well, those products are doing very well as we speak. the multiple is pretty low, it seems like earnings are basing around $11 and they're probably going to tick up from here. so, i feel like it's pal

bloomberg reporting that eli lilly planning to start clinical trials. stephanie haines has the story. >> pediatricians could soon be adding weight loss shots to their arsenal in the fight against childhood obesity. online records show drug company. eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports. it is in phase 3 of a study that began in 2021. for kids ages 6 to 12 for end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's like it's going to do much if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of to crease cream time. according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up.

stuart: what have you got on eli lilly? lauren: just for you with.proval for not just diabetes, which it has, but also for weight loss. bank of america says this stock is going to $700. stuart: whoa! now that's, that should have come first. lauren: well, i wanted to give you microsoft -- can oh, you mean in telling of the eli lilly. stuart: you buried the lead. all right, now this, the women's swim squad at roanoke college in virginia is fighting to keep a transgender athlete, a biological male, from joining their team. david spunt has the story. all right. this trans-athlete recently competed for the men's team, didn't they? >> reporter: that's exactly right. and several of the women's swim member few that team member. members of the women's swim team are upset, they're calling on the ncaa to make changes and do it now. according to the team, the trans swimmer originally on the men's team. some of those swimmers knew they were on the men's team. now, former college swimmer or riley gaines, an advocate for keeping women's sports teams made up of biol

eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports.n phase 3 of a study that began in 2021. for kids ages 6 to 12 for, end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's unlikely it's going to do much if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of you know, to chris green time, according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up. you do need to. >> look at each situation and >> add the lifestyle, the painter, the teaching intensively and they're so it can't look at it like a way to each case is different. and you can't just even the older kids. it's important to know that these drugs, we don't kno

eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports. in phase 3 of a study that began in 2021. for kids ages 6 to 12 for end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's like it's going to do much if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of you know, to chris green time, according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up. you do need to. >> look at each situation and the lifestyle, the painter, the teaching intensively and they're so. >> it can't look at it like a way to each case is different. and you can't just even the older kids. it's important to know that these drugs, we don't know the

and we go v by targeting the hormones that kick in after people eat eli lilly hopes to get fda approval for the drug treat lost by the end of the year. coming up in the next hour of morning news, community members are planning rally oakland, mayor sheng thao. >> she gets ready to deliver her state of the city address. tell you the issues they are demanding be addressed. and gas prices kept rising last month. now they're going down. tell you why. what you can tell you why. what you can expect. palm. just between us, you know what's better than mopping? anything! ugh. well, i switched to swiffer wetjet, and it's awesome. it's an all-in-one, that absorbs dirt and grime deep inside. and it helps prevent streaks and haze. wetjet is so worth it. love it, or your money back. >> from the area's local news station, you're watching the kron. 4 morning news at 6. >> good morning. thank you for joining us here on the kron. 4 morning news. i'm james fletcher. yes, and i'm daria and we've got a lot of headlines to get to which will do in a minute. but first, we want to take a look at the weather. it

eli lilly believes this'll give it access to therapies that enable the precise targeting of cancer eors clearly see a positive future for warby parker after ever core upgraded the company from in line to outperform. shares moving higher by 3.5, a price target of $20 for the stock expecting revenue margin growth for the prescription eye glass manufacturer. ever core estimates 40 new physical stores in 2024 will support war by's retail sales growth. shares right now stand at $13.74, so a bit of a way to go before $20 the but still getting a bump here. and mccormack losing some of its spice after reporting third quarter sales that missed analyst expectations, attributing the miss to a slower than expected economic recovery in china and the exit of some businesses. the spice maker did raise its annual profit forecast, expecting higher prices to offset lower demand. i use the pumpkin spice, right, in my coffee every morning. okay. would you pay $14 a month to scroll through instagram feeds on your phone without ads in "the wall street journal" says parent meta platforms is working on it r

ely lilly is an amazing company. the last pull-back, we've seen this before. every time it's been bought, that proved to be the case. the question is going to come at some point, valuation is going to get in the way. if you are looking for places that make sense, mdt is an interesting play. >> for lilly, it's hard to justify at the moment, right? as a value investor, it's hard to be long this, but i do think this is such an extraordinary case. we don't know how big it's going to get. obviously it has tons of hype, which we don't normally love, but i feel like it's -- i made a mistake before of inning it, both novo and lilly and just thinking, oh, my god, they have gotten out of control and getting out of both and then had to buy lilly much higher, so -- than where i sold it. i don't want to make that same mistake again, but i do think it is getting a bit frothy here. the way for me to look at it, it would be to sell some upside calls. i do want to have say in the story, but these reactions a are -- i mean, i'm very interested, we were talking about this on the

we own eli lilly for the charitable trust and talk about it endlessly and do so with a reason. its drug might become the greatest selling pharmaceutical of all time. >> the house of pain! >> all aboard! >> well, you know, i'm excited. it just hit an all-time high today of $605, up $25 in this one session. so after a day where the dow gained 66 points. the s&p climbed 0.43%, the nasdaq jumped.71%, the way concepts seem to get ahead of themselves in the stock market. let me set the stage. weekly injection drugs that help people with type 2 diabetes by lowing their glucose levels. novo nordisk's drug called wegovy has also been approved to help with weight loss because it suppresses appetite and curbs hunger. it is a runaway success. it's always being used off label because it has the same mechanism as novo nordisk. it's in very short supply because of demand. we've known that these glp-1 drugs could impact many different industries, but nobody thought that would happen any time season until walmart, one of the nation's largest grocers last week mentioned them as a reason for a de

eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports.ase 3 of a study that began in 2021. for kids ages 6 to 12 for end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's unlike that's going to do much if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of you know, to chris green time, according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up. you do need to. >> look at each situation and the lifestyle, the painter, the teaching intensively and they're so. >> it can't look at it like a way to each case is different. and you can't just even the older kids. it's important to know that these drugs, we don't know the lo

and eli lilly is better there. >> harker is on the tape this morning. fed official, of course.e're at the point where we can hold rates where they are. rates are restrictive, disinflation is under way. we're going to hear from powell next week, jim. >> that's good. i wish these guys would all shut up. i mean it seriously. they're confusing the markets. they're not doing anything that i find valuable. i've spoken at the rotary, okay? just keep it high-level about the neighborhood. there's absolutely no reason that patrick harker had to do one thing to deviate from the narrative that bryce harper is the single best acquisition we've ever had. that's it. i mean, just stop it. talk about the eagles. and then say, listen, things are fine. i don't like these people who every day come up with a different view. who are they? they're just -- he was -- i like him, but we have a fed chair. he's very smart. and it would really help him if they just said, you know what, i defer to the fed. just say that over and over again. no one's going to dislike you. no one. but no, they feel like they

that showed a significant impact on how much people were eating for those who don't know, it's the eli lilly'sreatment drug >> so let's run through some of the companies, who you think is most exposed to least? >> sure. in our view, the companies that are most affected are companies with high exposure to snacking our work and the study shows that there's a significant shift in people's behaviors. we see this as are asshaving ne impact, lose hershey, mondelesz and kellanova. also fast-food snacks. we see the companies as not positioned to benefit from this. >> what about the granddaddies of them, pepsi, frito-lay, and coke >> i covered the packaged food companies, i don't cover the beverage companies, but over time, companies will adapt, coke actually made comments on their earnings call yesterday that they're already well positioned to benefit from a shift to less calorie consumption. this was amazing to mow. mounjaro experienced a 71% reduction of lunch intake once taking the medicine. >> the impact is very striking a 70% reduction in calories consumed at lunch. people lost 7% of their body w

. >> you actually recently visited one of eli lilly's manufacturing plants. what was that like?, there are so many people who wants to be on medicines like this. lilly makes a medicine called mounjaro, a different one than looked at in this study. same amemechanism. they're investing $2 billion in a plant in north carolina. we got an exclusive look at those turning out millions of these auto injects of mounjaro over the year. we talked with them how they can go any faster because there's a shortage of these drugs. here's what they said. >> it's a massive scale what we're trying to do. i don't think we've ever done this as a company or anybody else in the country who has scaled this. >> you can move any faster than you're going? >> we're going as fast as we can, but we have to follow certain controls to make sure the final product meets expectations. >> so, boris, these drugs aren't yet approved. but this specific rug not yet approved for obesity. but people can seek it out as they get approve for obesity for the end of the year. >> meg, thank you. >>> other headlines we're watch

. >> i think is right two pharma companies nova nortisel and eli lilly on a tear weight suppression drugsink continue to do well, the broader sector healthcare xlv, the index down 4% year-to-date but i went back last four quarters up all four quarters, 10 1/2% on average then look at unh13 biggest in dow down 4% year-to-date, as technician i look at these above moving afrmz i think rally to 550, seven% in cards will hope averages a little bit of broadening out seven stocks pulled back dramatically held on wouldn't shock me a nice rally in nvidia microsoft google into final quarter. maria: i feel ai placed dot com -- stock would go up happening today great insight from you as usual jaywoods joining us quick break biden border crisis spiraling out of control rick scott is here to join he has been to the border multiple times, we will talk about it. . ♪ . just keep ♪ ♪ . loving this pay bump in our allowance. wonder where mom and dad got the extra money? maybe they won the lottery? maybe they inherited a fortune? maybe buried treasure? maybe it fell off a truck? maybe they switched to xfinit

procter & gamble of course, general mills, pfizer, merck, eli lilly. investors flock to the companies that generate safe earnings. because you don't stop eating food or brushing your teeth in a recession. why is this distinction so important? why is it the first piece of wall street jargon i'm translating? it helps you figure out how much companies will earn in a given environment, and the money managers, the hedge fund play book is when to buy or sell these type of stocks based on what the economies of the world are doing. in the old days, 50% of the performance of an individual stock came from the sector, the segment of the economy it falls into, tech, energy, machinery, health care. when it comes to sectors, much of the moves are driven whether they fall into secular or cyclical camps. it's much more now than 50%. you don't want to own much cyclical when the economy is slowing, they'll get crushed because the earnings tend to fall apart as they have during every meaningful slowdown. including chinese slowdowns. nothing about that we can do, what do

eli lilly is planning to test the diabetes judrug in kids who have obesiobesity.n of its drugs in kids as young as 6 and shares of those companies are mixed this morning. eli lilly is up. >>> elon musk says his social media company x, or twitter, will launch two tiers of sub descrs subscrippss for users. a full slate of ads and another o will not have ads. it will test a $1 a year fee for users to post as a way to fight spam or bot activity. >>> the department of energy wants to buy 6 million barrels of oil for the strategic reserve. it is hoping to get a price of $79 or less. it is working to refill the spr after president biden ordered his or toric release to try to high gas prices. buy low, sell high. i'm not sure that's what we're doing here. there was a time. >> briefly. we could have filled it at lower rates. >> it does get scary. no one was expecting the middle east to totally be a different place than what we saw or thought it was six months ago sdplcago. >> if you looked at oil prices three weeks ago, energy has come down 10% in ten days. wti. there was a

shares of eli lilly down. alternative energy stocks are sinking on concerns of the general economic picture but more so the impact of what you were talking about, scott, growth focused companies. sunrun down 9% is array. chargepoint and bloom energy also well over at least 5% lower. >> kristina, we'll talk to you. >>> more on the sell-off on mega cap tech. the nasdaq dropping 2%. the biggest moves and the health of that tech trade at-large. we're live from the new york stock exchange. when you think of investment risk, do you consider climate risk? changing weather patterns are impacting the way we live and the value of businesses large and small. this can mean disruption to supply chains, changing demand for products and shifting regulation. what does this mean for your business, your clients, and your investments? ice offers data and markets that can provide critical insight. manage your climate risk with ice. nice footwork. man, you're lucky, watching live sports never used to be this easy. now you can stre

alix: at least we have in eli lilly so there is that.man sachs pointed out that is potential -- maybe we'll be talking about novo nordisk versus amazon with lvmh. i was looking at the holders and tried to get her bernard arno or jeff bezos for novo nordisk but i cannot find it. guy: i think it is more evenly spread. alix: the gap between lvmh and novo has widened rapidly. that is the new narrative out of europe. no longer dominated by the luxury story. it is a health technology. i want to talk to about some of the stocks we are watching. we were just talking about stellantis, getting a nice upgrade. stellantis getting a nice start. barclays behind the wheel on the stocks. the stock is currently trading at $18.85. this is interesting as the whole world was focusing on those strikes in the united states. we will see where that goes. another stock is airbus. this is a nice story. jeffrey seeing a buyback story coming onto the horizon. the cash flow generation very strong. we will hear from airbus shortly. $150 price target. erickson, and no

and i love to see eli lilly make the top 10 list. this is all about moon gyro.etes drug that will certainly get approved for weight loss along with a ton of other medications. and they have had flawless execution down the pipeline. and we bought this stock only to be pleasantly surprised. amazing, one home voter they made the top 10. we know that homebuilders remains a strong, much longer than anyone thought. and partly because we've had such an unattainable housing shortage. a percent mortgage rates are bad for business. but it is hard to get to negative on this. i think there is a natural flaw under them even though others were chattering all day about how bad they are doing and how low they will go. bottom line, those are the 10 best performance since the market bottomed a year ago. some can keep winning and others have lost the race. we are increasingly worried once again about the economy let's go to roy in california. >> hey, jimmy chill. >> chill is in the house. >> i try to be witty here with this all jerry lewis will be called boring, boring. it's not s

let's begin with eli lilly. lauren: it is up one. 2%. the head of the diabetes and obesity division, mike mason, will retire at the end of the year. why is this important? what we he oversaw the late stage development of madero which is a diabetes drug and they hope to get it to fight obesity but he will be leaving, another executive placing him there. carnival cruise lines. guess what is out of style? the revenge travel, go anywhere, pay anything, now we want relaxing, intentional travel. what's more relaxing than a cruise assuming you don't get sick, all the cruise lines are at the top of the s&p 500 today. sun run, truest price target at $12, down from the initial one, $30, higher interest rates will continue to be a head wind for residential solar. it is down 6-one/3%. stuart: i like relaxed managed to travel you get all the benefits. let's move on. kevin o'leary is a frequent guest on the show. he showed stocks on the changing crypto landscape. what is he saying? lauren: pioneers who he calls cowboys will be pushed out by delay of r

the s&p 500 companies report stateside including apple, chip giants amd and qualcomm along with eli lillyzer we heard from hsbc this morning. soc gen and metro bank with results this week. it is a big week for the energy giants with bp and shell due to report tomorrow. novo will be out with numbers and we will closely watching reports from bmw and stellantis. >> you are chatting in the wilderness, which i feel i do all the time, what about supply? ever since i looked at the analysis with the congressional budget office analysis of the supplier bond looks like up to 2030 and beyond, i have been trying to balance it out and no one has taken attention. >> the market has taken note >> now, everyone is talking about issuance now i feel i have to move on >> the bond vigilantes have been asleep for a while now thanks to the central banks. qt is slowly waking up >> i don't do the reads. the u.s. treasury is likely to increase the size of bonds and bills in the fourth quarter. the treasury will help fund a budget deficit with increasing borrowing costs. this is not going away it is all of a sudden

. >> as it the stock price look at that in stark contrast to the eli lillies of the world or the eli lilly of the world >> i took a picture yesterday of twinkies, the hostess twinkie, i don't know, you buy a thing of doughnuts, you only want one doughnut >> you want to do ms pick? >> no. i'm going to deny your request i will do endeavor >> you are picking the picker. >> they'll talk to picker later. james gorman and the incoming ceo of morgan stanley, ted pick. let's talk about this, the stock is up 18%. endeavor, remember, of course, most recently in the news because of the merger of its usc with wwe creating tko of which they control it. go back to the ipo, back in april of '21 i believe it was, you can see, it's not been a good performer that's including the move up today. that's frustrated ari emanuel who runs the company and maybe even silver lake, its largest stakeholder and the company that controls endeavor. late yesterday we got this given the continued dislocation between our public market value and the intrinsic value of our underlying assets, we believe an evaluation of st

bloomberg is reporting that novo nordisk and eli lilly is exploring weight loss drugs for kids as youngg to bloomberg. both drugmakers testing weight loss drugs for kids as young as 6. >>> still ahead, jay powell's speech yesterday and the dow looks like it would open up 60 points lower right now. we're watching the ten-year yield as we watch that to move to 10%. we see it move throughout the morning. looking at the bond picture with the ten-year yield at 4.94%. with that, let's bring in jeff kilburg, counter erfounder of k financial. great to see you. >> great to see you, frank. >> what was your take on what you heard from jay powell yesterday? >> actually, i thought jay powell was dovish. i know initially the market reacted to that. the ten-year yield went to 4.90%. he hedged himself and he talked about being resolute. you talked about that earlier on the show. that put the bond vigilantes back in the captain's chair. they ran the ten-year yield back to 5%. they achieved that target of 5%. when you digest what powell was saying, it was a dovish tilt. you saw the fmoc watch tool. it de

eli lilly up in sympathy with the weight loss drug now being apparently effective kidney disease anding up 2.7% as well. we take a look at the s&p 500 and the macro, we are going to see that it is well-off of the 200 day moving average. whether this is some kind of a bottoming pattern is unclear. we are going to see it move back lower. if we take a look at the 10 year yield this year, we are going to see this big, big rise, really unsustainable. this is starting to consolidate back down to the trend. looks like we could see the 10 year yield go back to 430. at that point, i would say there is some real volatility for the markets. we don't know if that will be the typical relationship we have with yields down, stocks up. never a dull day, moment or week. alix: abigail, thank you very much. exxon mobil is expected to trim annual cost by about $2 million as it integrates with pioneer natural resources. >> you have to become a diversified company. the question is, do we do it ourselves or do we become part of a company like exxon mobil? exxon mobil has the best around the world, the best

ashley: were out of time but you like constellation energy at eli lilly. a little more concerned about your doom and gloom outlook for a big drop in the markets but thank you for your time. appreciate it. come back in, lauren, you're looking at the movers, let's begin with a familiar name. american express. lauren: is down 4%. third-quarter profit at american express stronger-than-expected but in a sign of caution they boosted their provisions for credit losses by 58% from last year and that would account for the increased likelihood of wealthier american express customer defaulting on their debt and that's why stock is down. take a look at her tnt moving in the other direction, it's up 9% in the past two days, up 31/4 following earnings they got an upgrade to outperform. the firm really like their free cash flow and expect that to improve. crux is also higher. they were upgrading to purchase at raymond james, the stock is up 3%, price target 110. raymond james believes it is oversold as a stock and based on the checks on stores and social media they are r

but eli lilly already worked i would go with an angen who hasn't had a bill wind yet i would stick withne. >> all right there is a lot more fast one to come here's what's coming up next >>> okay, boomer bank of america says youth is overrated. we'll dive into a generational pairs trade that could put the baby boom back in your portfolio. >>> plus, the diamond dump jp morgan's ceo is doing something he's never done, waiving good-bye to a million shares of the company. how much should we read into this sale? we'll get some answers next. you're watching "fast money," live from the nasdaq market site in times square. we're back right after this. ♪ when better money habits® content first started coming out, it expanded what i could do for special olympics athletes with developmental needs. thousands of bank of america employees like scott spend countless hours volunteering to teach people how to reach their financial goals. it felt good. it felt like i could take on the whole world. power e*trade's award-winning trading app makes trading easier. with its customizable options chain, easy-to-u

. >>> later this hour from bristol-myers this weekend to eli lilly last week, health care and biotech appears to be picking up. who might be next and how might investors benefit? we'll talk about that. >> we're watching shares of tesla. jeffries cut its price target from $250 to $265 implying 4% downside but that stock up 3.3%. the firm saying margin erosion in the third quarter and uncertain growth in 2024 still raises questions about the company's earlier profit edge. stay with us. since my citi custom cash® card automatically adjusts to earn me more cash back in my top eligible category... suddenly life's feeling a little more automatic. like doors opening wherever i go... [sound of airplane overhead] even the ground is moving for me! y'all seeing this? wild! and i don't even have to activate anything. oooooohhh... automatic sashimi! earn cash back that automatically adjusts to how you spend with the citi custom cash® card. [mind blown explosion noise] >>> welcome back. we're watching shares of pepsi this morning. a beat and a raise has shares in the green. up about 1.1%. but it's

. >> bloomberg reports said ely ely lilly is planning to start clinical trials. news nation.ians could soon be adding weight loss shots to their arsenal in the fight against childhood obesity. online records show drug company. eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports. it is in phase 3 of a study that began in 2021. for kids ages 6 to 12 for end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's like it's going to do much if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of you know, to crease cream time. according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up. you do need to. >> look at each sit

eli lilly, we know about those -- proctor got her today because it's been hurt because of the gop becauseis happens to be a well-run bank. bank, auto company, consumer packaged good company, cybersecurity company and a drug company. once again, i am blessing this. i am blessing this. do we have time for greg in texas? greg? >> caller: boo yeah, my brother. i've got exxon, delta airlines, draftkings, freeport mac moran, sm ci. am i diversified? >> i miss the third one. what was the third one? okay. draftkings. got it. let's go to work here. draftkings, jason robin doing a terrific job. let's call that gaming. freeport, largest copper company in the country, exxon mobil, big dog. we know that, although chevron is bigger. delta, they report next week. and a little technology here. tech, minerals, gaming, oil, and gas, airline, again, everyone passed. everyone passed. maybe making it too easy. franco in new york? >> caller: hello, sir, how are you? >> i am good, chief. what is happening? >> caller: here are my stocks. i have gold barrack, charles schwab, kellogg, ralph lauren, and pepsico. am

eli lilly will buy the business. those shares up. back in two. gold isn't merely a commodity. it's an investment in people and communities. at osisko, we strive to build modern, safe, and sustainable mines that benefit all. think big. shape tomorrow. osisko. here in hawaii there is always time. there's time to spend with family, time to enjoy with friends. there's always time to listen or lend a helping hand. here we have all the time in the world, but no time to waste. >>> watching the spice maker mccormick down 9%. earnings come in in line. revenue short. sales volume decline and management noted weakness, specifically in the asia-pacific region saying china's economic recovery has been slower than anticipated. the stock is at more than three-year low. i think they raised guidance but analysts were pinpointing that to strength in the mexican jb, which they thought was not the best reason for the guidance range. overall, though, it wasn't like super weak. down 2% on back of higher prices. >> it is a tough market to report anything into. food-related staples have had a tough t

. >> thank you >> beautiful >>> still ahead, earnings season rolls on with mcdonald's, eli lilly andeport next week. we'll get the trade on each of those in "three stock lunch. ♪ is it possible to fall in love with your home... ...before you even step inside? ♪ discover the magnolia home james hardie collection. available now in siding colors, styles and textures. curated by joanna gaines. here's why you should switch fo to duckduckgo on all your devie duckduckgo comes with a built-n engine like google, but it's pi and doesn't spy on your searchs and duckduckgo lets you browse like chrome, but it blocks cooi and creepy ads that follow youa from google and other companie. and there's no catch. it's fre. we make money from ads, but they don't follow you aroud join the millions of people taking back their privacy by downloading duckduckgo on all your devices today. the current analyst consensus is strong buy with average price target representing 25 here with our trades is art hogan, chief market strategist art, great to see you. how are you looking at mcdonald's >> i can tell you this,

the biggest country -- company in all of europe or, right in lie are lily, heir trying to get -- eli lillyle. stuart: we only started talking about those drugs, what, eight months ago? >> it's going to be the a.i. of drugs. there's a correlation there, right? a.i. just skyrocketed and nobody was talking about it two years ago, now these drugs skyrocketing. stuart: i think we've got time for a few more if earnings reports that came out earlier today, general electric. look at it go. lawrt. lauren: planes are flying for longer periods of time so they need more service, double-digit growth in orders for them, cash flow. final point, not only do did they raise their full-year profit forecast, they did so for the third time. stuart: have we got time for raytheon? lauren: stock up almost 6%. stuart: huge gains today. lauren: yep, good day. stuart: border patrol warns that hamashezbollah fighters could be coming across our border, southern border. are they already here? good question. >>> president biden wants more than $100 billion in aid for israel and ukraine. will congress approve it? senate

eli lilly is starting a clinical trial foreman jaro on patients ages 6 to 11 novo nordisk reports. it is in phase 3 of a study that began in 2021. for kids ages 6 to 12 for, end up. pediatricians say regardless of the study the first line of treatment needs to focus on changing lifestyle and behavior. it's unlike that's going to do much. if you just give medication, you need to instill all these. >> few changes, lifestyle changes. talk about the diet, nutrition, consulates, the exercise, the moving, the lack of you know, to chris green time, according to the cdc, close to 15 million children suffer from obesity and data shows kids may have gained weight twice as fast during the pandemic. earlier this year, the american academy of pediatrics came out with new guidance, suggesting medication or surgery in patients 12 and up. you do need to. >> look at each situation and add the lifestyle. the painter, the teaching intensively and they're so. >> it can't look at it like a way to each case is different. and you can't just even the older kids. it's important to know that these drugs, we

especially with this new weight loss and new eli lilly drug, i was at this establishment recently.of planet fit in th fitness? >> i have a huge believer before. until they have a new ceo, i'm a l lime time guy. martin in florida. martin. martin? i think i hear cramer. what have you got, martin? >> oh, hi, jim. i would like to know about mgm grand in las vegas. what do you think? >> i think it's okay. the stock's down a lot. we own wynn for the charitable trust and jeff marks knows it better than anyone and i think that is the better one to own. let's dgo to robert in michigan. robert. >> yes, how are you doing? >> well. how are you? >> my question is is at&t a good stock to buy. >> it's not my favorite. i have been negative on verizon. that conference call today was very good so i've got to be more positive on that. but i remain a stalwart for t mobile. let's go to jay in new york. jay. >> hey, professor. i'd like to know your opinion on drs. should i buy more? i have some shares. >> i own it. the answer's yes and i don't like to usually be that -- without being paid. qualitative.

stuart: you like novo nordisk and eli lilly -- >> the weight loss drugs.friend, right? these are two stocks that are up 48% is and 66% year to date respectively. only 1% of americans are currently prescribed one of these weight loss drug, that's going to go up to 7-10% in the next decade, that's a compelling momentum trade to take a look at. this is, obviously, the tailwind is there for these stocks whereas you're seeing a headwind in food stocks because of these ozempic weight loss drugs which i think is totally overblown. stuart: i agree. >> there's 1% of the population on that, do you know how many people are now smoking marijuana and getting the munchies? [laughter] we get a counterbalance of the weight loss and marijuana. stuart: got it. thanks, lou. defense secretary addressedded concerns on whether or not the u.s. can support both israel and the ukraine. jennifer griffin with us. can we support both at the same time, jennifer? >> reporter: well, defense secretary lloyd austin spoke the morning from nato headquarters after two days of meetings with d